Hoe verhoudt INDOCO's PE Ratio zich tot zijn concurrenten?

INDOCO is duur op basis van de Price-To-Earnings -ratio ( 92 x) vergeleken met het gemiddelde van de peer ( 49 x).

Hoe verhoudt INDOCO's PE Ratio zich tot andere bedrijven in de IN Pharmaceuticals industrie?

INDOCO is duur op basis van de Price-To-Earnings -ratio ( 92 x) vergeleken met het Indian Pharmaceuticals -industriegemiddelde ( 31.7 x).

Wat is INDOCO's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

INDOCO is duur op basis van de Price-To-Earnings Ratio ( 92 x) vergeleken met de geschatte Fair Price-To-Earnings Ratio ( 74.6 x).

Wat is de reële prijs van INDOCO als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

INDOCO ( ₹320.05 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( ₹816.02 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is lager dan de huidige aandelenkoers.

Indoco Remedies (NSEI:INDOCO) - Aandelenkoers, Nieuws & Analyse

INDOCO Overzicht aandelen

Indoco Remedies Limited produceert, verkoopt en verhandelt formuleringen en actieve farmaceutische ingrediënten in India en daarbuiten. Meer informatie

INDOCO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	1/6
Financiële gezondheid	3/6
Dividenden	3/6

Beloningen

Verhandeld tegen 60.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 72.18% per jaar groeien

Risicoanalyse

Hoog niveau van niet-contante inkomsten

Rentebetalingen worden niet goed gedekt door de winsten

Winstmarges (1.8%) zijn lager dan vorig jaar (6.5%)

Dividend van 0.47% wordt niet goed gedekt door vrije kasstromen

Indoco Remedies Limited Concurrenten

Gujarat Themis Biosyn

BSE:506879

₹34.0b

Themis Medicare

BSE:530199

₹26.6b

SMS Pharmaceuticals

NSEI:SMSPHARMA

₹20.4b

RPG Life Sciences

NSEI:RPGLIFE

₹32.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Indoco Remedies
Historische aandelenkoersen
Huidige aandelenkoers	₹320.05
52 Week Hoogtepunt	₹415.00
52 Week Laag	₹286.60
Bèta	0.44
11 maand verandering	-0.17%
3 maanden verandering	-12.01%
1 Jaar Verandering	-9.36%
33 jaar verandering	-22.15%
5 jaar verandering	96.17%
Verandering sinds IPO	508.85%

Recent nieuws en updates

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Recent updates

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

May 24

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Jan 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Sep 16

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

May 21

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Aug 31

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Jul 04

Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price

Mar 09

What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?

Feb 22

Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?

Feb 07

Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 17

Is Indoco Remedies (NSE:INDOCO) A Risky Investment?

Dec 27

Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)

Dec 06

What Type Of Shareholders Own The Most Number of Indoco Remedies Limited (NSE:INDOCO) Shares?

Nov 14

Rendement voor aandeelhouders

	INDOCO	IN Pharmaceuticals	IN Markt
7D	3.4%	0.5%	0.5%
1Y	-9.4%	42.5%	27.5%

Rendement versus industrie: INDOCO presteerde slechter dan de Indian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 42.5 % opleverde.

Rendement versus markt: INDOCO presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van 27.5 % opleverde.

Prijsvolatiliteit

Is INDOCO's price volatile compared to industry and market?
INDOCO volatility
INDOCO Average Weekly Movement	3.9%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.1%
10% most volatile stocks in IN Market	9.1%
10% least volatile stocks in IN Market	4.0%

Stabiele aandelenkoers: INDOCO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van INDOCO is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1945	6,000	Sundeep Bambolkar	www.indoco.com

Indoco Remedies Limited produceert, verkoopt en verkoopt formuleringen en actieve farmaceutische ingrediënten in India en internationaal. Het biedt stomatologische, gastro-intestinale, respiratoire, anti-infectieuze, vitaminen/mineralen/nutriënten, oftal/ontologische, dermatologische, urologische, anti-diabetische, gynaecologische, lifestyle management, pijn/analgetische en hartproducten aan. Het bedrijf levert ook generieke merkproducten, waaronder pijnstillende tabletten en topische preparaten; bloeddrukverlagers; eiwitsupplementen; multivitaminetabletten en -siropen; antibioticatabletten, -siropen en injecteerbare producten; orale rehydratiepoeders; maagzuurremmers; en antihistaminica, evenals antiaremorroïdale crèmes en calciumpreparaten.

Indoco Remedies Limited Samenvatting

Hoe verhouden de winst en inkomsten van Indoco Remedies zich tot de beurswaarde?
INDOCO fundamentele statistieken
Marktkapitalisatie	₹29.50b
Inkomsten(TTM)	₹320.60m
Inkomsten(TTM)	₹17.73b

92.0x

Koers/Winstverhouding

1.7x

P/S-verhouding

Is INDOCO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
INDOCO resultatenrekening (TTM)
Inkomsten	₹17.73b
Kosten van inkomsten	₹6.23b
Brutowinst	₹11.51b
Overige uitgaven	₹11.18b
Inkomsten	₹320.60m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	3.48
Brutomarge	64.88%
Nettowinstmarge	1.81%
Schuld/Eigen Vermogen Verhouding	75.2%

Hoe presteerde INDOCO op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.5%

Huidig dividendrendement

14%

Uitbetalingsratio

INDOCO Overzicht aandelen

Beloningen

Risicoanalyse

Indoco Remedies Limited Concurrenten

BSE:506879

₹34.0b

BSE:530199

₹26.6b

NSEI:SMSPHARMA

₹20.4b

NSEI:RPGLIFE

₹32.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Recent updates

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

Consensus EPS estimates fall by 20%

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

Consensus EPS estimates fall by 16%

Full year 2024 earnings: EPS misses analyst expectations

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Consensus EPS estimates fall by 13%

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly